Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Prostatic Neoplasms 103Lymphoma, Large B-Cell, Diffuse 32Neoplasms 23Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 20Lymphoma 19Multiple Myeloma 15Lymphoma, B-Cell 11Neoplasm Metastasis 10Recurrence 8Lymphoma, T-Cell, Peripheral 7Prostatic Neoplasms, Castration-Resistant 5Prostate Cancer Metastatic 5Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Mantle-Cell 5Hematologic Diseases 5Lymphoma, B-Cell, Marginal Zone 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Pain 2Metastatic Castration Resistant Prostate Cancer 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia 2Graft vs Host Disease 2

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × Prednisone × Clear all
NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡